Business
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco\n\n\nSOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced key research highlights from its synthetic lethality pipeline. IDEAYA's research in synthetic lethality comprises multiple preclinical programs against novel targets with genetically defined biomarkers, including:\nMethionine adenosyltransferase 2a (MAT2A) inhibitors for solid tumors with methylthioadenosine phosphorylase (MTAP) deletions DNA polymerase theta (Polq) inhibitors for solid tumors with homologous recombination deficiency (HRD), such as BRCA mutations Werner helicase (WRN) inhibitors for tumors with high microsatellite instability (MSI-High) Poly (ADP-ribose) glycohydrolase (PARG), in tumors with Replication Stress Novel undisclosed synthetic lethality targets undergoing validation\nDr. William Sellers, M.D., a member of IDEAYA's Scientific Advisory Board and a Core Institute Member of the Broad Institute of MIT and Harvard, noted that \"Synthetic lethality is an important area of cancer biology that has the opportunity to deliver the next generation of targeted therapies for patients. The industry advancement in molecular biology research tools, including CRISPR, has enabled our ability to interrogate key biological questions to validate novel targets. MAT2A and Werner Helicase represent two of the most exciting synthetic lethality targets to emerge since PARP inhibitors.\"\n\"We are excited about the progress across our synthetic lethality pipeline targeting patient populations such as MTAP-deletion, HRD, and MSI-High. We have advanced multiple potential first-in-class programs to in vivo testing, and have also validated the synthetic lethal biology for novel undisclosed targets,\" said Dr. Michael Dillon, Ph.D., Senior Vice President, Chief Scientific Officer and Head of Research at IDEAYA Biosciences. \nKey research highlights and target milestones for IDEAYA's pipeline in synthetic lethality include:\nMAT2A (MTAP) Monotherapy activity with robust tumor grow...